皮下埋入式多功能化疗导管肝血管灌注治疗晚期肝癌68例  

Treating 68 eases of late hepatic cancer by hepatic vascular perfusion with hypodermic implanted muti—used ehemotheraputic catheter

作　　者：田建国[1] 鲁自祥[1] 张宏伟[1] 薛焕州[1] 姜青峰[1] 张焕常 王明吉[1] 

机构地区：[1]河南省人民医院外科

出　　处：《临床医学》1993年第4期152-154,共3页Clinical Medicine

摘　　要：我们1991年5月至1992年6月经皮下埋入式多功能化疗导管肝动脉和(或)门静脉ADR、FUDR 灌注治疗晚期肝癌68例。本文详述了置导管的方法及化疗的结果。48例术后带瘤者中16例 AFP (甲胎蛋白)降至正常(33.33%)。53例肿瘤缩小,中位缩小率74.1%,缩小50%占64.15%,6例残留癌块消失,6例门脉癌栓消失。该法较全身化疗毒副反应轻,化疗时具有无菌性,易操作管理等特点。为预防肿瘤切除疑有癌组织残存的大肝癌复发、主瘤切除残留癌肿、合并门脉癌栓等晚期肝癌的治疗检查建立了永久性血管通道。68 cases of late liver cancer had been treatedunder hapatic artery or portal vein ADR,FUDR perfusion withmultifunctional implantable Drug Delivery Systems from May,1991 to June,1992.The implantation method and the result ofchemotherapy were illustrated in this article.In 48 cases withcancer after operation,16 cases decreased in AFP to normal(33.33%).53 cases of cancer shrink in size and the medianshrinking rate is 74.1%.It is 64.15% which was shrinkingmore half in size than original cancer.6 cases of residual cancerand 6 cases of portal embolus disappear.The less toxic or sideeffect,bacteria free and easy control are its strong points contrastwith whole body chemotherapy.A permanent vascilar passagehas been built in order to prevent large liver cancer recurrenceafter cancer exeission,to prevent residual cancer after majorcancer excision and to prevent Complicating portal cancerembolus.

关 键 词：肝动脉 门静脉灌注 肝肿瘤 

分 类 号：R735.705[医药卫生—肿瘤]